Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2009, Vol. 14 ›› Issue (9): 1074-1080.
MIAO Cai-yun1, CHEN Jiang-fei2
Received:2009-04-23
Revised:2009-08-06
Published:2020-11-03
CLC Number:
MIAO Cai-yun, CHEN Jiang-fei. Advance in research for pharmacokinetics on antifugal drug of itraconazole[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(9): 1074-1080.
Add to citation manager EndNote|Ris|BibTeX
URL: https://manu41.magtech.com.cn/Jweb_clyl/EN/
https://manu41.magtech.com.cn/Jweb_clyl/EN/Y2009/V14/I9/1074
| [1] Hardin TC, Graybill JR, Fetchick R, et al.Pharmacokinetics of itraconazole following oral administration to normal volunteers[J]. Antimicrob Agents Chemother, 1988, 32(9):1310-1313. [2] May DB, Drew RH, Yedinak KC, et al. Effect of simultaneous didanosine administration on itraconazole absorption in healthy volunteers[J]. Pharmacotherapy, 1994, 14(5): 509-513. [3] Barone JA, Koh JG, Bierman RH, et al. Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers[J]. Antimicrob Agents Chemother, 1993, 37(4):778-784. [4] Lange D, Pavao JH,Wu J, et al. Effect of a cola beverage on the bioavailability of itraconazole in the presence of H2 blockers[J]. J Clin Pharmacol, 1997, 37(6):535-540. [5] Jaruratanasirikul S, Kleepkaew A.Influence of an acidic beverage (Coca-Cola) on the absorption of itraconazole[J]. Eur J Clin Pharmacol, 1997, 52(3):235-237. [6] Jaruratanasirikul S, Sriwiriy ajan S. Effect of omeprazole on the pharmacolinetics of itraconazole[J]. Eur J Clin Pharmacol, 1998, 54(2):159-161. [7] Barone JA, MoskovITA BL, Guarnieri J, et al. Enhanced bioavailability of itraconazole in hydroxypropyl-β-cyclodextrin solution versus capsules in healthy volunteers[J]. Antimicrob Agents Chemother, 1998, 42(7):1862-1865. [8] Van de Velde V, Van Peer AP, Heykants JJ, et al.Effect of food on the pharmacokinetics of a new hydroxypropyl-betacyclodextrin formulation of itraconazole[J]. Pharmacotherapy, 1996, 16(3):424-428. [9] Barone JA, MoskovITA BL, Guarnieri J, et al.Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers[J]. Pharmacotherapy, 1998, 18(2):295-301. [10] JohnsonMD, Hamilton CD, Drew RH, et al.A randomized comparative study to determine the effect of omeprazole on the peak serum concentration of itraconazole oral solution[J]. J Antimicrob Chemother, 2003, 51(2):453-457. [11] Kawakami M, Suzuki K, Ishizuka T, et al. Effect of grapefruit juice on pharmacokinetics of itraconazole in healthy subjects[J]. Int J Clin Pharmacol Ther, 1998, 36(6):306-308. [12] Penzak SR, Gubbins PO, Gurley BJ, et al. Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers[J]. Ther Drug Monit, 1999, 21(3): 304-309. [13] Gubbins PO, McConnell SA, Gurley BJ, et al.Influence of grapefruit juice on the systemic availability of itraconazole oral solution in healthy adult volunteers[J]. Pharmacotherapy, 2004, 24(4):460-467. [14] Gubbins PO, Gurley BJ, Williams DK, et al. Examining sex-related differences in enteric itraconazole metabolism in healthy adults using grapefruit juice[J]. Eur J Clin Pharmacol, 2008, 64(3):293-301. [15] Reynes J, Bazin C, Ajana F, et al.Pharmacokinetics of itraconazole (oral solution)in two groups of human immunodeficiency virus-infected adults with oral candidiasis[J]. Antimicrob Agents Chemother, 1997, 41(11):2554-2558. [16] Darouiche RO, Setoodeh A, Anaissie EJ.Potential use of a simplified method for determination of itraconazole levels in plasma and esophageal tissue by using high-performance liquid chromatography[J]. Antimicrob Agents Chemother, 1995, 39(3):757-759. [17] Conte JE Jr, Golden JA, Kipps J, et al. Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state[J]. Antimicrob Agents Chemother, 2004, 48(10):3823-3827. [18] Morimoto K, Tanuma H, Kikuchi I, et al.Pharmacokinetic investigation of oral itraconazole in stratum corneum level of tinea pedis[J]. My coses, 2004, 47(3/4):104-114. [19] Seishima M, Oyama z, Oda M, et al.Distribution of an antifungal drug, itraconazole, in pathological and non-pathological tissues[J]. Eur J Dermatol, 2004, 14(1):24-27. [20] Havu V, Brandt H, Heikkila H, et al.Continuous and intermittent itraconazole dosing schedules for the treatment of onychomycosis: a pharmacokinetic comparison[J]. Br J Dermatol, 1999, 140(1):96-101. [21] Gupta AK, Groen K, Woestenborghs R, et al.Itraconazole pulse therapy is effective in the treatment of Majocchi's granuloma: a clinical and pharmacokinetic evaluation and implications for possible effectiveness in tinea capitis[J]. Clin Exp Dermatol, 1998, 23(3):103-108. [22] Miyama T, Takanaga H, Matsuo H, et al. P-gly coproteinmediated transport of itraconazole across the blood-brain barrier[J]. Antimicrob Agents Chemother, 1998, 42(7): 1738-1744. [23] Imbert F, JardinM, Fernandez C, et al. Effect of efflux inhibition on brain uptake of itraconazole in ice infected with Cryptococcus neoformans[J]. Drug Metab Dispos, 2003, 31(3):319-325. [24] Isoherranen N, Kunze KL, Allen KE, et al.Role of itraconazole metabolites in CYP3A4 inhibition[J]. Drug Metab Dispos, 2004, 32(10):1121-1131. [25] Kunze KL, Nelson WL, Kharasch ED, et al. Stereochemical aspects of itraconazole metabolism in vitro and in vivo[J]. Drug Metab Dispos, 2006, 34(4):583-590. [26] Templeton IE, Thummel KE, Kharasch ED, et al.Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo[J]. Clin Pharmacol Ther, 2008, 83(1):77-85. [27] Ducharme MP, Slaughter RL,Warbasse LH, et al.Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin[J]. Clin Pharmacol Ther, 1995, 58(6):617-624. [28] Jaruratanasirikul S, Sriwiriyajan S. Effect of rifampicin on the pharmacokinetics of itraconazole in normal volunteers and AIDS patients[J]. Eur J Clin Pharmacol, 1998, 54(2):155-158. [29] Crommentuyn KM, Mulder JW, Sparidans RW, et al. Drugdrug interaction between itraconazole and lopinavir/ ritonavir in an HIV-1-infected patient with disseminated histoplasmosis[J]. Clin Infect Dis, 2004, 38(8):e73-e75. [30] Koo HL, Hamill RJ, Andrade RA.Drug-drug interaction between itraconazole and efavirenz in a patient with AIDS and disseminated histoplasmosis[J]. Clin Infect Dis, 2007, 45(6):e77-e79. [31] Jaruratanasirikul S, Sriwirivajan S.Pharmacokinetic study of the interaction between itraconazole and nevirapine[J]. Eur J Clin Pharacol, 2007, 63(5):451-456. [32] Timmers GJ, Kessels LW,Wilhelm AJ, et al.Effects of cyclosporine on a single-dose pharmacokinetics of intravenous itraconazole in patients with hematologic malignancies[J]. Ther Drug Monit, 2008, 30(3):301-305. [33] Boelaert J, Schurgers M, Matthys E, et al.Itraconazole pharmacokinetics in patients with renal dysfunction[J]. Antimicrob Agents Chemother, 1988, 32(10):1595-1597. [34] Mohr JF, Finkel KW, Rex JH, et al. Pharmacokinetics of intravenous itraconazole in stable hemodialysis patients[J]. Antimicrob Agents Chemother, 2004, 48(3):3151-3153. [35] Cavakier A, Leveque D, Peter JD, et al.Pharmacokinetics interaction between itraconazole and ceftriaxone in Yucatan miniature pigs[J]. Antimicrob Agents Chemother, 1997, 41(9):2029-2032. [36] Cartledge JD, Midgely J, Gazzard BG.Itraconazole solution: higher serum rates than the capsule formulation in acquired immunodeficiency syndrome patients with candidosis[J]. J Clin Pathol, 1997, 50(6):477-480. [37] Smith D, Van de Velde V, Woestenborghs R, et al. The pharmacokinetics of oral itraconazole in AIDS patients[J]. J Pharm Pharmacol, 1992, 44(7):618-619. [38] Zhao Q, Zhou H, Pesco-Koplowitz L.Pharmacokinetics of intravenous itraconazole followed by itraconazole oral solution in patients with human immunodeficiency virus infection[J]. J Clin Pharmacol, 2001, 41(12):1319-1328. [39] Prentice AG, Warnock DW, Johnson SAN, et al.Multiple dose pharmacokinetics of an oral solution of itraconazole in patients receiving chemotherapy for acute myeloid leukaemia[J]. J Antimicrob Chemother, 1995, 36(4):657-663. [40] Michallet M, Persat F, Kranzhofer N, et al.Pharmacokinetics of itraconazole oral solution in allogeneic bone marrow transplant patients receiving total body irradiation[J]. Bone Marrow Transplant, 1998, 21(12):1239-1243. [41] Hennig S,Wainwright CE, Bell SC, et al. Population pharmacokinetics of itracoanzole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients[J]. Clin Pharmacokinet, 2006, 45(11):1099-1114. [42] BoogaertsMA,Maertens J, Van der Geest R, et al.Pharmacokinetics and safety of a 7-day administration of intravenous itraconazole followed by a 14-day administration of itraconazole oral solution in patients with hematologic malignancy[J]. Antimicrob Agents Chemother, 2001, 45(3): 981-985. [43] Vandewoude K, Vogelaers D, Decruyenaere J, et al.Concentration in plasma and safety of 7 day of intravenous itraconazole followed by 2 week of oral itraconazole solution in patients in intensive care unit[J]. Antimicrob Agents Chemother, 1997, 41(12):2714-2718. [44] De Repentigny L, Ratelle J, Leclerc JM, et al. Repeateddose pharmacokinetics of an oral solution of itraconazole in infants and children[J]. Antimicrob Agents Chemother, 1998, 42(2):404-408. [45] Schmitt C, Perel Y, Harousseau JL, et al.Pharnacokinetics of itraconazole oral solution in neutropenic children during long-term prophylaxis[J]. Antimcrob Agents Chemother, 2001, 45(5):1561-1564. |
| [1] | WU Yujie, ZHAO Chengcheng, XI Qing. Evaluation of tegacycline regimens in treatment of gram-negative bacterial infections with Monte Carlo simulation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1027-1033. |
| [2] | LI Kun, LI Lulu, LI Nannan, HU Weihong, ZHOU Jianchao. Effects of glycaemic control and CYP3A5 polymorphisms on tacrolimus trough concentrations after adult kidney transplantation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 767-774. |
| [3] | HE Xueru, LI Ying, MA Yinling, FU Yuhao, XUN Xuejiao, DONG Zhanjun. Pharmacokinetic interaction study between sorafenib and dapagliflozin in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 498-507. |
| [4] | HUANG Zhiwei, LI Yi, XU Xiaoyong, ZHANG Lei, SHEN Yifeng, LI Huafang. Comparison of calculation results of five population pharmacokinetic analysis tools [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 525-535. |
| [5] | LI Mengxue, HE Jie, YU Xiaxia, HU Linlin, SHAO Hua. Research progress in population pharmacokinetics of rituximab [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 468-474. |
| [6] | YAN Qiangyong, XIANG Daxiong, ZHU Ronghua, YANG Lingfeng, YANG Xiding, LI Jingjing, FAN Xiao, LIU Sai, XIONG Shoujun, FANG Pingfei. Bioequivalence study of cinacalcet hydrochloride tablets in healthy Chinese volunteers [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 171-177. |
| [7] | LIU Lu, SHI Yufei, HE Qingfeng, XU Fengyan, WANG Kun, CAI Weimin, XIANG Xiaoqiang. Application of population modeling analysis to evaluate the impact of gene polymorphism on drug PK/PD [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1275-1282. |
| [8] | ZHOU Jiating, ZHANG Xuan, XIE Zilan, LI Zhi. Interactions and clinical significance of gut microbiota and levothyroxine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1307-1314. |
| [9] | LI Xuejing, JIANG Jinping, LI Sining, WAN Linfei, ZHOU Xiangxiang, YANG Lian, LAN Ke. A bioequivalence study of generic and brand clozapine in schizophrenic patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1121-1130. |
| [10] | WU Lili, LIANG Zhi, HUANG Siyong, WANG Yan. Effect of augmented renal clearance (ARC) on the pharmacokinetics, efficacy, and safety of vancomycin in patients with infective endocarditis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1139-1145. |
| [11] | MA Shen, LIU Yushuo, TANG Hui, CHEN Wenbin, GAO Ling. Pharmacokinetics and clinical significance of drugs for improving nonalcoholic fatty liver disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 908-918. |
| [12] | DAI Jingyi, WANG Jingjing, ZHANG Jing, YU Jicheng, LI Nanyang, HUANG Zhiwei. Clinical application and research progress of inhaled methoxyflurane [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 808-813. |
| [13] | PAN Shu, WU Yijin, ZHANG Sasa, WANG Qihai, LUO Tingting, YIN Qin. Pharmacokinetics of methotrexate mediated by organic anion transporter 3 in adjuvant induced arthritis rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 516-525. |
| [14] | WU Juan, WANG Zhiqiang, ZHOU Renpeng, YANG Jingjing, QIN Huiling, ZHANG Qian, LU Chao, HU Wei. Bioequivalence trial of fasting oral sorafenib tosylate tablets in healthy Chinese subjects [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 281-286. |
| [15] | ZHANG Jinhua, LIU Maobai, CAI Mingzhi, ZHENG Yingli, LAO Haiyan, XIANG Qian, DU Liping, ZHU Zhu, DONG Jing, ZUO Xiaocong, LI Xingang, SHANG Dewei, CHEN Bing, YE Yanrong, WANG Yuzhu, GAO Jianjun, ZHANG Jian, CHEN Wansheng, XIE Haitang, JIAO Zheng. Model informed precision dosing of warfarin: China expert consensus report (2022 version) [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1201-1212. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
